June 27, 2019
            Subaru Corporation Announces Production, Japan Sales and Export Results
for May 2019 (Flash Report)
< May 2019 >
| May 2019 | Jan-May 2019 | ||||
| Units | 2019 vs 2018 | Units | ’19 vs ’18 | ||
| Domestic production *1 | 
 50,088  | 
+14.9% | First y/y increase in 10 months | 
 230,291  | 
-14.7% | 
| Overseas production *2 | 
☆☆ 40,069  | 
+35.5% | 11th consecutive month of y/y increase | 
 176,358  | 
+20.3% | 
| Global production total | 
☆ 90,157  | 
+23.2% | 2nd consecutive month of y/y increase | 
 406,649  | 
-2.3% | 
| Passenger vehicles | 7,129 | +9.1% | 2nd consecutive month of y/y increase | 46,373 | -8.3% | 
| Mini vehicles | 1,869 | -6.8% | 6th consecutive month of y/y decrease | 11,064 | -20.1% | 
| Japan sales total | 8,998 | +5.3% | 2nd consecutive month of y/y increase | 57,437 | -10.8% | 
| Export total *3 | 
 36,303  | 
+5.4% | First y/y increase in 7 months | 
 177,374  | 
-19.4% | 
☆: May record
☆☆: All-time record for any month
< Production >
| - | Domestic production increased year-on-year, due to a significant increase in Forester production which offset an impact of changes in plant operation schedules continuing since November 2018. | 
| - | Overseas production increased year-on-year boosted by production of Ascent which started in May 2018 as well as increases in other models. | 
< Sales in Japan >
| - | Passenger vehicle sales increased year-on-year, led by the fully-redesigned Forester launched in July 2018 as well as increased sales of the Subaru XV driven by strong demand for its “e-Boxer”-equipped models. (e-Boxer: Subaru’s newly-developed power unit system that combines a 2.0-liter horizontally-opposed, direct injection Subaru Boxer engine with an electric motor.)  | 
| - | Mini vehicle sales decreased year-on-year due to decreased sales of the Chiffon and other models. | 
< Exports >
| - | Exports from Japan increased year-on-year due to increased shipments of the Forester. | 
*1 JAMA (Japan Automobile Manufacturers Association Inc.) report basis (CBU)
*2 Local line-off basis
*3 JAMA report basis
###